Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (41-50 of 205) with videos related to

Pageof 21
Sort By:
Plos One|August 19, 2016
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesLaura N Eadie, Timothy P Hughes, Deborah L White
Leukemia|April 15, 2018
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapyLaura N Eadie, Timothy P Hughes, Deborah L White
Journal of Cellular and Molecular Medicine|April 21, 2009
Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitroStephen J Blake, A Bruce Lyons, Timothy P Hughes
Clinical Immunology (Orlando, Fla.)|April 9, 2008
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitroStephen Blake, Timothy P Hughes, Graham Mayrhofer, et al.
Clinical Chemistry|July 22, 2008
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual diseaseDavid M Ross, Dale B Watkins, Timothy P Hughes, et al.
Cancers|July 27, 2022
Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid LeukaemiaGovinda Poudel, Molly G Tolland, Timothy P Hughes, et al.
International Journal of Hematology|July 3, 2015
Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemiaJeremy Ong, David Yeung, Robin Filshie, et al.
Leukemia & Lymphoma|June 5, 2012
Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagyLisa Schafranek, Tamara M Leclercq, Deborah L White, et al.
Immunology and Cell Biology|January 22, 2005
Imatinib inhibits the functional capacity of cultured human monocytesAndrea L Dewar, Kathleen V Doherty, Timothy P Hughes, et al.
Leukemia Research|May 22, 2007
International standardisation of quantitative real-time RT-PCR for BCR-ABLNicholas C P Cross, Timothy P Hughes, Andreas Hochhaus, et al.
Pageof 21

Showing results (41-50 of 205) with videos related to

Sort By:
Pageof 21
Plos One|August 19, 2016
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell LinesLaura N Eadie, Timothy P Hughes, Deborah L White
Leukemia|April 15, 2018
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapyLaura N Eadie, Timothy P Hughes, Deborah L White
Journal of Cellular and Molecular Medicine|April 21, 2009
Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitroStephen J Blake, A Bruce Lyons, Timothy P Hughes
Clinical Immunology (Orlando, Fla.)|April 9, 2008
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitroStephen Blake, Timothy P Hughes, Graham Mayrhofer, et al.
Clinical Chemistry|July 22, 2008
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual diseaseDavid M Ross, Dale B Watkins, Timothy P Hughes, et al.
Cancers|July 27, 2022
Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid LeukaemiaGovinda Poudel, Molly G Tolland, Timothy P Hughes, et al.
International Journal of Hematology|July 3, 2015
Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemiaJeremy Ong, David Yeung, Robin Filshie, et al.
Leukemia & Lymphoma|June 5, 2012
Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagyLisa Schafranek, Tamara M Leclercq, Deborah L White, et al.
Immunology and Cell Biology|January 22, 2005
Imatinib inhibits the functional capacity of cultured human monocytesAndrea L Dewar, Kathleen V Doherty, Timothy P Hughes, et al.
Leukemia Research|May 22, 2007
International standardisation of quantitative real-time RT-PCR for BCR-ABLNicholas C P Cross, Timothy P Hughes, Andreas Hochhaus, et al.
Pageof 21